has served as our Chief Executive Officer since co-founding Inventiva in 2011, and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager of Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master’s degree in Business Administration from INSEAD, a master’s degree in International Relations from Johns Hopkins University and a bachelor’s degree in Economics from Paris IX Dauphiné University.
Pierre Broqua, Ph.D.
has served as our Chief Scientific Officer since co-founding Inventiva in 2011, and as our Deputy Chief Executive Officer as well as a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He is a Doctor of pharmacology from the University of Paris Descartes and also has a master’s degree in Chemistry and Biochemistry from the Université Pierre et Marie Curie, Paris.
has served as our Chief Financial Officer since August 2012. Previously, Mr. Volatier was a senior consultant for I Care Environnement, a consulting company, from January 2011 to October 2011, he also served as the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010, as the Chief Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008, as the Financial Director — International Operations of Laboratories Fournier, from 1999 to 2006 and finally, as the Head of Controlling for URGO Soins & Santé Laboratories, a pharmaceutical company, from 1996 to 1999. Mr. Volatier began his career at PriceWaterhouseCoopers, where he worked from 1989 to 1996. He holds a master’s degree in Management from Paris IX Dauphiné University, PSL University, an executive specialized master’s degree in Corporate Social Responsibility from MINES-ParisTech, PSL University, and the “Diplôme d’Études Supérieures Comptables et Financières”.
Dr. Michael Cooreman
Chief Medical Officer
Prior to joining Inventiva in October 2020, Dr. Michael Cooreman has been Vice President, Science and Medicine, in charge of Global Research and Development, Gastroenterology and Hepatology, at Ferring Pharmaceuticals in the U.S. since 2017. He previously held numerous U.S.-based positions as CMO and Executive Director in global roles at leading pharmaceutical and biotechnology companies, including Takeda Pharmaceuticals, Merck, Mitsubishi Tanabe, ImmusanT and Novartis, covering the four major regulatory regions U.S., EU, Japan and China. Over the years, Dr. Cooreman has developed a strong expertise in translational medicine, clinical pharmacology and clinical product development.
Of dual US and Belgian citizenship, Dr. Cooreman is trained as an internist and gastroenterologist-hepatologist, with a special interest in metabolic and immune-mediated liver and gastrointestinal diseases, as well as viral hepatitis, cirrhosis and oncology. He holds a Doctor of Medicine degree from the University of Louvain, Belgium, and a doctorate from the Heinrich Heine University in Dusseldorf, Germany.
Kristina Meyer, Ph.D.
Kristina Meyer brings more than 15 years of commercial and business development experience in the biotech industry. Kristina joined Inventiva in 2015 from Oxford BioTherapeutics where she was responsible for the outlicensing of pre-clinical oncology assets, inlicensing of antibody arming technologies, oncology target discovery collaborations and alliance management. Prior to Oxford BioTherapeutics she worked at Evotec in the USA and the UK where she had regional commercial responsibility for the discovery alliance business across various therapeutic areas and territories. Dr. Meyer holds a PhD. in organic chemistry from the University of Frankfurt, Germany, and conducted post-doctoral research at Yale University in New Haven, CT, USA.